Migraine
Conditions
Keywords
Erenumab,, CGRP,, real world evidence,, sick leaves,, working impairment,, health care visits,, prescriptions,, migraine
Brief summary
This was a retrospective registry-based study utilizing data collected in association with clinical care of patients. All data was stored in electronic health records at Terveystalo data base, and no patients were contacted for the study.
Detailed description
Patients initiating erenumab treatment between 20.9.2018 - 15.10. 2019, and data on sick leave days, diagnoses and health care visits as well as medications based on prescriptions were assessed. Following time frames for analyses of sick leaves and health care utilization in patients on erenumab treatment and in controls were reported: Follow-up analyses: For cases (erenumab) with occupational healthcare, a minimum of 12 months on erenumab treatment was required for the analysis of sick leaves and visits Pre erenumab: Follow-up data before index (defined as the first reimbursement decision/prescription for erenumab, or initiation of erenumab injections (before reimbursement approval)) from the Terveystalo database of those with consent Post erenumab: Follow-up data after index, from the Terveystalo database of those with consent Time frames for comparison (sick leaves and visits): One year before index vs. \>12 months erenumab after index, One year before index vs. 6-12 months of erenumab after index (patient years), sensitivity analysis Time frames for comparison (medications): 12 months before index vs. 12 months post follow-up Controls (triptan treated migraine patients): Corresponding time frames as in cases.
Interventions
OTHERErenumab
Patients who met the responder definition of two or more erenumab prescriptions with no evidence of switch to other CGRPi were included in the main analyses
Sponsors
Novartis Pharmaceuticals
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* Adult patients on erenumab treatment ATC: N02CX07 * Diagnosis of migraine (ICD G43) * Consented * Occupational healthcare
Exclusion criteria
None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of sick leave days (headache) | throughout the study, approximately 2 years | Sick leaves included migraine or head-ache related registered sick leave days at Terveystalo in the occupational healthcare cohort and controls. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in number of sick leave days (all cause) | throughout the study, approximately 2 years | Sick leaves included all registered sick leave days at Terveystalo in the occupational healthcare cohort and controls. |
| Change in number of healthcare visits (head-ache related) | throughout the study, approximately 2 years | Number of headache related healthcare visits were reported. |
| Change in number of healthcare visits (all cause) | throughout the study, approximately 2 years | Number of healthcare visits were reported. |
| Medication patterns: Number of patients receiving medications of interest | throughout the study, approximately 2 years | The number of patients receiving medications of interest in erenumab treated patients in migraine patient controls were reported. |
Countries
United States
Outcome results
None listed